Pituitary TSH deficiency is a form of central hypothyroidism in which the thyroid gland, although potentially intact, receives insufficient stimulation because the pituitary gland does not secrete TSH in adequate quantity and quality, or secretes it in a manner that is not aligned with the body’s physiological needs. In this context, the key parameter is not TSH elevation, which is typical of primary hypothyroidism, but the finding of reduced peripheral availability of thyroid hormones with low, normal, or inappropriately “non-elevated” TSH. The condition often occurs within the broader framework of hypopituitarism and reflects diseases of the sellar and parasellar region, outcomes of surgery or radiotherapy, inflammatory or infiltrative processes, vascular events, medications, and, in some situations, iatrogenic autoimmune mechanisms such as immunotherapy-related hypophysitis.
TSH deficiency has relevant clinical implications because central hypothyroidism is frequently underdiagnosed: the automatic interpretation of TSH as a reliable “sensor” can mask hormonal deficiency and delay treatment. Management therefore requires a pathophysiological approach centered on measurement and monitoring of FT4, complete assessment of the other pituitary axes, and correction of the most important therapeutic priority, namely any adrenocorticotropic hormone (ACTH) deficiency, which must be recognized and treated before starting levothyroxine in order to avoid acute decompensation.
Central hypothyroidism accounts for a minority of all cases of hypothyroidism, which are dominated by autoimmune or iatrogenic primary hypothyroidism, but it has disproportionate relevance in specialist settings involving pituitary disease. Its prevalence in the general population is low, and estimates are affected by underdiagnosis, especially in mild forms or in situations where FT4 lies at the lower end of the reference range. In centers following patients with pituitary adenomas, craniopharyngiomas, parasellar lesions, or after surgery and radiotherapy, the frequency of thyrotropic deficiency is instead significant and often coexists with ACTH and gonadotropin deficiencies, confirming the selective and progressive vulnerability of different pituitary cell types to compressive, surgical, and radiation-induced injury.
Among the main acquired risk factors, tumors of the sellar and parasellar region represent a central determinant. Nonfunctioning pituitary adenomas and macroadenomas, through mass effect and impairment of pituitary parenchyma, can reduce TSH secretion; similarly, craniopharyngiomas and suprasellar lesions can alter both pituitary function and hypothalamic integration, producing mixed clinical pictures. Pituitary surgery can cause transient or permanent deficiency depending on the extent of the procedure, anatomical complexity, and the presence of functional residual tissue. Cranial radiotherapy, particularly with relevant doses and volumes or techniques involving the hypothalamic-pituitary axis, is associated with an increasing risk of hypopituitarism that rises with follow-up duration, making prolonged endocrine surveillance necessary.
Vascular events such as pituitary apoplexy and postpartum ischemic syndromes, including Sheehan syndrome, can lead to multiple deficiencies, including thyrotropic deficiency, with onset that may be subacute or delayed. Inflammatory and autoimmune processes of the pituitary gland, such as lymphocytic hypophysitis, and infiltrative conditions such as sarcoidosis, histiocytosis, tuberculosis, or metastases can alter TSH secretion. An increasingly relevant area is hypophysitis related to immune checkpoint inhibitors, in which thyrotropic deficiency is frequent and may coexist with corticotropic deficiency, requiring a timely diagnostic and therapeutic pathway to prevent complications.
On the pharmacological side, several medications can reduce TSH or alter its secretion, including high-dose glucocorticoids, dopamine agonists, and somatostatin analogues. These conditions do not always correspond to true structural deficiency, but they can simulate central hypothyroidism or contribute to making it clinically manifest in predisposed individuals. The epidemiological picture, therefore, should not be interpreted as an “absolute rarity”, but as a disease with selectively high prevalence in populations with pituitary disease, cranial treatments, and immunotherapy, where clinical suspicion must be proactive.
Pituitary TSH deficiency results from impaired function of the thyrotrophs, the anterior pituitary cells responsible for TSH production, or from disconnection of hypothalamic control mediated by thyrotropin-releasing hormone (TRH). Under physiological conditions, hypothalamic TRH stimulates TSH synthesis and secretion, while thyroid hormones exert negative feedback on the hypothalamus and pituitary gland. TSH, by binding to the thyroid receptor, supports iodination, synthesis and secretion of T4 and T3, and maintains follicular trophism. In central deficiency, the thyroid may be structurally normal, but chronic reduction of stimulation leads to inadequate production of thyroid hormones, with reduced FT4 and often reduced T3, especially in more advanced forms or in contexts of comorbidity.
The causes may be compressive, iatrogenic, inflammatory, infiltrative, vascular, or genetic. In sellar tumor diseases, the mass effect compromises perfusion and integrity of pituitary tissue, reducing secretory reserve. After surgery, loss of functional tissue and fibrosis can determine permanent deficiencies. After radiotherapy, damage may be progressive, with a latency period of years, because the radiosensitivity of cells and of the vascular microenvironment produces gradual deterioration of pituitary function. In hypophysitis, inflammation and edema alter secretion and may evolve into fibrosis with persistent deficiencies; in immunotherapy-mediated forms, pathogenesis includes lymphocytic infiltration and direct immunological injury, often with a pattern of multiple deficiencies.
A distinctive feature of central hypothyroidism is that measured TSH may not reflect biological activity. TSH is a glycoprotein whose glycosylation influences half-life and bioactivity; abnormalities in glycosylation and pituitary processing may produce immunoreactive but less active TSH, with values that appear normal or mildly elevated despite low FT4. In addition, loss of circadian rhythm and adaptive response to feedback makes the system less “reactive” to peripheral changes. This explains why diagnosis cannot be based on TSH thresholds, and why levothyroxine treatment monitoring must use FT4 as the biological target.
At the pathophysiological level, thyroid hormone deficiency reduces thermogenesis and energy expenditure, alters lipid metabolism with increased LDL cholesterol, reduces myocardial contractility, and may promote bradycardia and exercise intolerance. At the neuromuscular level, it contributes to asthenia, cramps, and psychomotor slowing. Central hypothyroidism also interacts with the other axes: the presence of GH deficiency, hypogonadism, and corticotropic deficiency can amplify symptoms and metabolic alterations and mask the specific contribution of thyroid hormone deficiency. This integration makes it essential to consider the patient as a “system of axes” rather than as a single isolated hormone.
The medical history must explore both symptoms of hypothyroidism and clues suggesting underlying pituitary disease. Thyroid-related symptoms may be subtle and progressive: asthenia, sleepiness, cold intolerance, modest weight gain, constipation, dry skin, cognitive slowing, reduced physical performance, and, in some cases, depression or apathy. In women, menstrual irregularities and reduced fertility may appear, often in synergy with hypogonadotropic hypogonadism. In patients with sellar disease, the history may include headache, visual disturbances, reduced libido, symptoms of adrenal insufficiency, polyuria or polydipsia, or a history of pituitary surgery, radiotherapy, or oncological treatment with immunotherapy.
On physical examination, typical signs of hypothyroidism may be present but are not always marked: cold and dry skin, bradycardia, reduced reflexes, mild non-pitting edema, hoarse voice, and psychomotor slowing. Goiter is not a central feature and, if present, points toward a concomitant thyroid etiology rather than an exclusively central cause. In parallel, signs of other pituitary deficiencies should be sought: hypotension, loss of androgen-dependent hair, pallor, reduced muscle mass, and neurological or visual signs suggestive of an expanding lesion.
In children and adolescents, the clinical picture has specific features: slowing of linear growth, delayed puberty, weight gain with reduced growth velocity, school difficulties, and reduced vitality. In this context, coexistence of GH deficiency or other tropic hormone deficiencies is frequent and can blur the clinical picture, requiring a complete endocrine assessment. In older patients or in those with cardiovascular comorbidities, symptoms may be attributed to other diseases, increasing the risk of delayed diagnosis and progression of metabolic and cardiovascular complications.
Suspicion of pituitary TSH deficiency should arise when the clinical picture is compatible with hypothyroidism but TSH is not elevated. The most typical scenario is low FT4 with low or normal TSH, or FT4 at the lower limit with symptoms and a risk context. Suspicion must be particularly high in patients with known sellar lesions, a history of pituitary surgery, cranial radiotherapy, craniopharyngioma, pituitary apoplexy, Sheehan syndrome, or hypophysitis, including immunotherapy-related hypophysitis. In these contexts, the interpretation “normal TSH, therefore the thyroid is fine” is misleading and potentially dangerous.
Another relevant context is the patient with already diagnosed hypopituitarism or with signs of multiple deficiencies. The coexistence of hypogonadism, reduced IGF-1, hyponatremia, severe asthenia, or hypotension requires an integrated assessment in which FT4 and TSH represent only part of the picture. In oncology patients treated with immune checkpoint inhibitors, the onset of headache, intense fatigue, hypotension, or thyroid-related symptoms should raise suspicion of hypophysitis and combined deficiencies, including thyrotropic deficiency.
However, it is essential to distinguish thyrotropic deficiency from conditions that can simulate reduced thyroid hormones without true central hypothyroidism, such as non-thyroidal illness syndrome and recovery phases after thyrotoxicosis or acute illness. Correct suspicion arises from integration of clinical context, stability of results, repeated testing, assessment of other pituitary tropic hormones, and imaging when indicated.
The diagnosis of pituitary TSH deficiency is based on recognition of a biochemical pattern and demonstration of a central disease or compatible context. The first step is measurement of FT4 and TSH using reliable methods, preferably repeated to confirm the result and reduce the impact of biological variability and analytical interference. The central operational criterion is the presence of reduced FT4, or FT4 in the lower range with strong clinical suspicion, associated with not adequately elevated TSH. FT3 may be reduced in advanced forms, but it is less specific because it is influenced by comorbidities and acute illness.
A crucial step is exclusion of the main alternative diagnoses that mimic central hypothyroidism. Non-thyroidal illness syndrome can reduce FT3 and, sometimes, FT4, with variable TSH, especially in hospitalized patients or those with severe systemic illness; in these cases, repeat testing at a distance and clinical assessment guide interpretation. Medications such as glucocorticoids, dopamine agonists, and somatostatin analogues can reduce TSH; biotin and heterophile antibodies can interfere with immunoassays, generating misleading results. For this reason, when there is discordance between clinical findings and laboratory results, it is appropriate to consider alternative methods, dilutions, repeat testing on different platforms, and specialist laboratory assessment.
After biochemical confirmation, assessment must include complete evaluation of the other pituitary axes, because central hypothyroidism is rarely isolated in acquired forms. The clinical priority is to identify any ACTH deficiency and central adrenal insufficiency, because starting levothyroxine in a patient with untreated cortisol deficiency can precipitate acute decompensation. Therefore, morning cortisol, ACTH and, when necessary, appropriate dynamic tests for the corticotropic axis must be integrated into the diagnostic pathway, together with prolactin, gonadotropins, IGF-1, and assessment of the ADH axis when indicated.
Pituitary magnetic resonance imaging with contrast medium is the key examination for identifying adenomas, infiltrative or inflammatory lesions, surgical outcomes, and structural abnormalities. Ophthalmological assessment with visual fields is indicated when compression of the chiasm is suspected. In selected cases, especially when the aim is to distinguish a hypothalamic defect from a pituitary defect or when the diagnosis is uncertain, the TRH test can provide information on reserve and on the dynamics of the TSH response, although it is not recommended as a routine test in all patients. Its clinical use is generally reserved for selected situations and interpreted in the context of FT4 and pituitary disease.
The outcome of the diagnostic pathway should be a diagnosis that is not limited to “central hypothyroidism”, but identifies the underlying cause and the status of the other axes, because treatment and prognosis depend on the baseline disease, the presence of multiple deficiencies, and evolution over time, especially after radiotherapy or immunotherapy.
The classification of central hypothyroidism first distinguishes between pituitary and hypothalamic forms, although in clinical practice the boundary may be blurred because of close anatomical and functional integration. In pituitary TSH deficiency, the primary damage involves thyrotrophs, with reduced secretion and sometimes reduced bioactivity of TSH; in hypothalamic deficiency, insufficient TRH stimulation predominates, with possible different dynamic responses to stimulation tests. A second classification axis separates congenital from acquired forms: congenital forms are rare and may present as isolated or syndromic deficiencies; acquired forms represent the majority in clinical pathways related to sellar lesions, surgery, radiotherapy, and hypophysitis.
It is also clinically useful to distinguish between isolated forms and forms occurring in the context of combined hypopituitarism. Isolated forms are less common in adults and require particular attention to alternative diagnoses and interference; combined forms are frequent and often include corticotropic and gonadotropic deficiencies, with immediate implications for treatment safety. Another element is transience: some conditions can determine temporary thyrotropic deficiency, such as the acute phase of hypophysitis or the early postoperative period, whereas others are typically progressive, such as radiation-induced damage or uncontrolled tumor expansion.
Severity is not assessed according to TSH, but according to FT4 level, symptoms, comorbidities, and patient vulnerability. A marked reduction in FT4, especially if associated with multiple deficiencies, carries a higher risk of metabolic, cardiovascular, and neuropsychiatric complications and requires faster and more protected therapeutic correction. In mild forms, assessment must consider that “low-normal FT4” may still be inappropriate for the patient, especially if the individual reference point was higher and if coexisting conditions amplify the clinical impact of thyroid hormone deficiency.
Treatment of pituitary TSH deficiency consists of replacement with levothyroxine (LT4), with one essential management principle: the dose is titrated using FT4 and clinical response, not TSH, which may remain low or inappropriate even in the presence of adequate replacement. Before starting LT4, it is essential to assess and, if present, treat a deficiency of the corticotropic axis, because the increase in metabolism induced by thyroid hormones can unmask or aggravate central adrenal insufficiency. This therapeutic priority is one of the most critical points in the clinical practice of hypopituitarism.
The initial LT4 dose depends on age, body weight, cardiovascular comorbidities, severity of deficiency, and desired speed of correction. In young adults without heart disease, a body weight-based strategy may be appropriate; in older patients or in those with ischemic heart disease, titration must be more gradual to reduce the risk of ischemia, arrhythmias, and heart failure. In pregnancy or in the preconception phase, the goal is to ensure adequate FT4 availability, because maternal-fetal physiology makes the early window of gestation particularly sensitive. In children, treatment must support growth and neurocognitive development, with age-specific dosing schedules and close follow-up.
The commonly adopted therapeutic target, consistent with European guidelines on central hypothyroidism, is to maintain FT4 in the mid-to-upper range of reference, adapting it to the patient’s clinical profile. Monitoring is typically performed after enough time has passed to reach LT4 steady state and after each dose change, integrating clinical assessment, heart rate, body weight, lipid profile, and subjective tolerance. Interactions and absorption issues must be considered, such as iron, calcium, proton pump inhibitors, sequestrant resins, intestinal diseases, and adherence. In patients receiving replacement therapy with GH, LT4 may need to be adjusted because GH can increase peripheral conversion and modify the FT4 balance, requiring dose reassessment.
Treatment must be integrated into a global plan for hypopituitarism when present, coordinating timing and priorities: cortisol replacement before LT4, correction of hypogonadism when indicated, assessment of the need for GH, and treatment of central diabetes insipidus when present. In this way, correction of thyroid deficiency becomes part of an integrated strategy that optimizes outcomes and safety, reducing the risk of overtreatment or undertreatment and improving long-term quality of life.
Follow-up of pituitary TSH deficiency requires structured monitoring because the context of pituitary disease is often dynamic. After starting or adjusting LT4, FT4 must be reassessed after an adequate interval for pharmacokinetic and clinical stabilization, together with clinical parameters such as heart rate, blood pressure, body weight, bowel function, physical performance, and neuropsychiatric status. Over time, once stability has been achieved, follow-up can be scheduled periodically, with higher frequency in case of major weight changes, pregnancy, introduction of interfering medications, or changes in other hormone replacement therapies.
In patients with hypopituitarism, follow-up must include reassessment of the other axes, because new deficiencies may appear after radiotherapy or with growth of residual tumor. Pituitary imaging is planned according to the underlying disease and neurosurgical and oncological decisions. In patients treated for adenomas or other sellar lesions, neuro-ophthalmological surveillance is indicated when there is a risk of chiasmal compression or progression. In oncology patients with immunotherapy-related hypophysitis, the trajectory may include partial recovery of some axes and persistence of other deficiencies, so reassessment must be personalized.
An essential clinical point is to prevent both undertreatment and overtreatment. Undertreatment maintains dyslipidemia, asthenia, reduced functional capacity, and cardiovascular risk; overtreatment increases the risk of tachyarrhythmias and bone loss, especially in vulnerable subjects. The absence of a “guiding” TSH requires more attentive medicine centered on FT4 and clinical findings, with coherent and verifiable goals over time.
The prognosis of pituitary TSH deficiency is generally favorable when diagnosis is timely and LT4 replacement is correct and stable, because central hypothyroidism is an effectively treatable condition. However, the overall outcome depends substantially on the underlying pituitary disease and the presence of multiple deficiencies. In patients with aggressive adenomas, infiltrative lesions, radiotherapy outcomes, or severe hypophysitis, prognosis is conditioned by the natural history of the baseline disease, the risk of recurrence or progression, and neurological and visual complications.
The main complications of untreated or undertreated thyrotropic deficiency include worsening lipid profile, increased cardiovascular risk, reduced work capacity and physical performance, cognitive and mood alterations, and, in children, impaired growth and development. In the context of hypopituitarism, thyroid deficiency can amplify sarcopenia and frailty, especially when hypogonadism and GH deficiency coexist. A relevant iatrogenic complication is the risk of adrenal crisis if LT4 is started in a patient with unrecognized corticotropic deficiency, which is why the therapeutic sequence is a prognostic component as important as the final LT4 dose.
Overtreatment, which is easier to produce when attempting to “normalize” a TSH that is not actually usable as a target, can promote osteoporosis, fractures, and arrhythmias, with prognostic impact especially in older patients. For this reason, long-term success is based on correct diagnosis, FT4-based monitoring, integrated management of the axes, and control of the underlying sellar or systemic disease. In this scenario, most patients can achieve satisfactory clinical stability and significantly reduce the risk of complications related to thyroid hormone deficiency.